Cortexyme (CRTX) Competitors

Omnicell (NASDAQ:OMCL) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings.

Which has more risk & volatility, OMCL or CRTX?

Omnicell has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.

Is OMCL or CRTX more profitable?

Omnicell has a net margin of 1.13% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 3.82% beat Cortexyme's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.13%	3.82%	2.07%
Cortexyme	N/A	-70.96%	-63.53%

Do analysts rate OMCL or CRTX?

Omnicell currently has a consensus target price of $50.67, indicating a potential upside of 62.08%. Given Omnicell's stronger consensus rating and higher probable upside, equities analysts clearly believe Omnicell is more favorable than Cortexyme.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cortexyme	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Which has better valuation & earnings, OMCL or CRTX?

Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.11B	1.32	$12.53M	$0.27	115.78
Cortexyme	N/A	N/A	-$89.94M	-$2.97	-0.38

Do insiders and institutionals hold more shares of OMCL or CRTX?

97.7% of Omnicell shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 2.5% of Omnicell shares are held by insiders. Comparatively, 27.9% of Cortexyme shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media prefer OMCL or CRTX?

In the previous week, Omnicell had 9 more articles in the media than Cortexyme. MarketBeat recorded 9 mentions for Omnicell and 0 mentions for Cortexyme. Omnicell's average media sentiment score of 1.06 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the media.

Company	Overall Sentiment
Omnicell	Positive
Cortexyme	Neutral

Does the MarketBeat Community favor OMCL or CRTX?

Omnicell received 349 more outperform votes than Cortexyme when rated by MarketBeat users. Likewise, 66.80% of users gave Omnicell an outperform vote while only 64.44% of users gave Cortexyme an outperform vote.

Company	Underperform	Outperform
Omnicell	Outperform Votes 503 66.80%	Underperform Votes 250 33.20%
Cortexyme	Outperform Votes 154 64.44%	Underperform Votes 85 35.56%

Summary

Omnicell beats Cortexyme on 15 of the 17 factors compared between the two stocks.